Iterum Therapeutics plc (NASDAQ:ITRM – Get Rating) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 4,180,000 shares, a growth of 56.6% from the April 15th total of 2,670,000 shares. Based on an average daily volume of 1,190,000 shares, the days-to-cover ratio is presently 3.5 days. Currently, 2.3% of the shares of the company are short sold.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC lifted its position in Iterum Therapeutics by 106.9% during the third quarter. Squarepoint Ops LLC now owns 52,503 shares of the company’s stock worth $29,000 after buying an additional 27,121 shares during the period. Franklin Resources Inc. purchased a new position in Iterum Therapeutics during the third quarter worth about $215,000. Morgan Stanley lifted its position in Iterum Therapeutics by 700.4% during the third quarter. Morgan Stanley now owns 456,410 shares of the company’s stock worth $255,000 after buying an additional 399,385 shares during the period. Virtu Financial LLC purchased a new position in Iterum Therapeutics during the fourth quarter worth about $164,000. Finally, Geode Capital Management LLC lifted its position in Iterum Therapeutics by 27.9% during the third quarter. Geode Capital Management LLC now owns 129,271 shares of the company’s stock worth $72,000 after buying an additional 28,169 shares during the period. 3.59% of the stock is currently owned by institutional investors and hedge funds.
Shares of Iterum Therapeutics stock traded up $0.02 during trading hours on Friday, hitting $0.22. 1,152,831 shares of the company were exchanged, compared to its average volume of 1,068,954. Iterum Therapeutics has a 1 year low of $0.19 and a 1 year high of $2.52. The company has a current ratio of 6.43, a quick ratio of 6.43 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average of $0.32 and a 200-day moving average of $0.40. The stock has a market capitalization of $39.95 million, a price-to-earnings ratio of -0.28 and a beta of 1.20.
Iterum Therapeutics Company Profile (Get Rating)
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
- Get a free copy of the StockNews.com research report on Iterum Therapeutics (ITRM)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.